Payment overview · 2025
General Payments
$876.92
40 reported records · 10 companies
Healthcare provider profile · identity verified
Archis D Desai, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · REDLANDS, CA · NPI 1396141230
Verified facts
What the public records show
CMS Open Payments records show Archis D Desai, M.D. received $876.92 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $190.65 | 21.7% | 17 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $177.62 | 20.2% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $125.70 | 14.3% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $121.91 | 13.9% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.24 | 8.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.83 | 6.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.18 | 6.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.15 | 3.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.13 | 2.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $22.51 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $876.92 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $190.65 | 17 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $177.62 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $125.70 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $121.91 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $110.01 | 4 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $74.24 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.15 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 514 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 404 | 34 |
| Lisinopril | Lisinopril | 268 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 245 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 177 | 12 |
| Omeprazole | Omeprazole | 168 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 26 |
| Metformin Hcl | Metformin Hcl | 132 | 20 |
| Gabapentin | Gabapentin | 131 | 21 |
| Ibuprofen | Ibuprofen | 126 | 28 |
| Losartan Potassium | Losartan Potassium | 117 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 12 |
| Simvastatin | Simvastatin | 80 | suppressed |
| Famotidine | Famotidine | 75 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 66 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | suppressed |
| Glipizide | Glipizide | 58 | suppressed |
| Topiramate | Topiramate | 58 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 16 |
| Finasteride | Finasteride | 56 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 18 |
| Furosemide | Furosemide | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 36 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Clotrimazole | Clotrimazole | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | 11 |
| Atenolol | Atenolol | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $876.92 · 40 records | ABBVIE INC. | CAPLYTA, INGREZZA, LYBALVI, Leqembi, Qelbree, REXULTI, SPRAVATO, VRAYLAR, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error